It's

already blowing up.

So I touched on, you know, our goal is to move a lot of the intelligence that used to live in a post-bill world to pre-bill.

And as we kind of set out, and I give our financial investors, CDNR and Towerbrook, a lot of credit.

Historically with R1, if you look at the acquisitions that have been done, it's more of your traditional M&A.

cash flowing businesses that are more mature, they're 10 years in and there's some synergies associated with it.

The two deals we've done since the take private with FAIR and now with Humada are a very different archetype and a different persona of entity that is really about accelerating our R&D roadmap aggregating access to clinical data and intelligence that on the front end can power not just one modular component like off, but a broader section of our end to end offering and then unlock the downstream ability to reduce denial.

What am I expecting?